StreetInsider.com News Articles

IceCure Medical expands U.S. sales team after 70% install base growth

Tue, 14 Jul 2026 08:33:26 -0400

IceCure Medical Ltd. (Nasdaq: ICCM) has expanded its U.S. sales and marketing teams, adding personnel in New York, Southern California, and the Midwest, along with additional clinical support staff, according to a press release dated July 14, 2026.

The expansion follows a previously reported 70% growth in the company's active U.S. commercial install base for its ProSense® cryoablation system, which the company attributed to FDA marketing authorization received in October 2025, clinical guidelines, and physician demand.

ProSense® is a liquid nitrogen-based cryoablation system used to destroy tumors by freezing. Procedures are now being performed in Los Angeles, New York, Atlanta, Dallas, Detroit,

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

Tue, 14 Jul 2026 08:32:00 -0400

CAESAREA, Israel, July 14, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive liquid nitrogen-based cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the expansion of its United States ("U.S.") sales and marketing teams.

In response to strong demand from leading hospitals and physicians across the country, the Company has strengthened its commercial team with

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

Tue, 14 Jul 2026 08:32:00 -0400

In response to strong demand from leading hospitals and physicians across the country, the Company has strengthened its commercial team with

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

Tue, 14 Jul 2026 08:32:00 -0400

In response to strong demand from leading hospitals and physicians across the country, the Company has strengthened its commercial team with

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

Tue, 14 Jul 2026 08:32:00 -0400

In response to strong demand from leading hospitals and physicians across the country, the Company has strengthened its commercial team with

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

Tue, 14 Jul 2026 08:32:00 -0400

In response to strong demand from leading hospitals and physicians across the country, the Company has strengthened its commercial team with

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

Tue, 14 Jul 2026 08:32:00 -0400

In response to strong demand from leading hospitals and physicians across the country, the Company has strengthened its commercial team with

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

Tue, 14 Jul 2026 08:32:00 -0400

In response to strong demand from leading hospitals and physicians across the country, the Company has strengthened its commercial team with

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

Tue, 14 Jul 2026 08:32:00 -0400

In response to strong demand from leading hospitals and physicians across the country, the Company has strengthened its commercial team with

IceCure reports ProSense cryoablation growth in Brazil after FDA nod

Mon, 06 Jul 2026 08:12:26 -0400

IceCure Medical Ltd. (NASDAQ: ICCM) highlighted growing commercial adoption of its ProSense cryoablation system in Brazil at the SOBRICE Onco 2026 interventional oncology congress, according to a company press release.

The Israel-based medical device company said commercial procedures using ProSense are already being performed in Brazil for breast, lung, kidney cancer, and musculoskeletal tumors. The system holds regulatory approval from Brazil's ANVISA, and IceCure's CEO Eyal Shamir said the recent U.S. Food and Drug Administration marketing authorization for early-stage, low-risk breast cancer has "provided significant tailwind, boosting awareness and interest among Brazilian physicians and institutions."

KTR Medical serves as IceCure's exclusive distributor

IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer

Mon, 06 Jul 2026 08:11:00 -0400

Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorization

Independent study evaluating breast cancer cryoablation in 750 patients across Brazil, led by renowned breast surgeon Dr. Vanessa Sanvido, is underway

Dr. Toulsie Ramtohul of Institut Curie, a ProSense™ user set to lead a 900-patient breast cancer cryoablation study in France, invited to key Brazilian hospitals and interventional oncology conference to share clinical expertise